BRAF and melanoma: In fact, on the one hand, the administration of a BRAFi in a BRAF-mutant melanoma model resulted in increased expression of CD40 ligand and interferon-gamma on tumor-infiltrating CD4+ lymphocytes (TILs) and decreased T-reg and myeloid cells on the other hand, suggesting antitumor modulation of the TME [23].